Roth Capital Reiterates Buy On Regeneron Pharmaceuticals Following Positive Trial Results
In a research report published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a $422 price target, as the company and partner Sanofi reported that the Phase IIa proof-of-concept study of dupilumab achieved the primary and all secondary endpoints. This study was done in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) that are unresponsive to standard of care.
Pantginis observed, “We believe this study broadens the clinical benefit profile of dupilumab, which is also in development for treatment of atopic dermatitis (AD) and asthma. Recall that in July, the Phase IIb study of dupilumab in patients with moderate-to-severe atopic dermatitis achieved the primary and the additional efficacy endpoints. The current Phase IIa proof-of-concept study suggests that dupilumab has a broad efficacy profile in allergic inflammation settings. Importantly, 58% of the CSwNP patients in the study also suffer from asthma and these two conditions are known to be co-morbid. This falls in line with the MOA of dupilumab, which targets two cytokines, IL-4 and IL-13, that play a key role in allergic response and inflammation through activation and maintenance of type 2 helper T cells. We believe that the data from this and previous Phase II studies in asthma and atopic dermatitis point to the strength of dupilumab as a drug targeting a central cytokine pathway governing allergic and inflammatory response.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -9.7% and a 30.6% success rate. Pantginis has a 34.5% average return when recommending REGN, and is ranked #3304 out of 3313 analysts.